Buchumschlag

Response to “The safety of semaglutide in patients with depression and obesity”

Fuente: Wiley Open Access

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	Robert F. Kushner, Thomas A. Wadden
Format:	Artículo Open Access
Veröffentlicht:	Wiley 2024
Schlagworte:	Obesity
Online-Zugang:	Acceder al recurso
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge

The safety of semaglutide in patients with depression and obesity
von: Ziyi Yang, et al.
Veröffentlicht: (2024)

Efficacy and safety of a novel oral hydrogel capsule in adults with overweight or obesity: the pivotal randomized RESET study
von: Jamy D. Ard, et al.
Veröffentlicht: (2025)

Psychiatric Safety of Tirzepatide in People With Obesity and No Known Major Psychopathology: A Post Hoc Analysis of SURMOUNT
von: Thomas A. Wadden, et al.
Veröffentlicht: (2026)

A GLP1R gene variant and sex influence the response to semaglutide treatment in patients with severe obesity
von: Aurélie Phan, et al.
Veröffentlicht: (2025)

Effect of semaglutide 2.4 mg on physical functioning and weight‐ and health‐related quality of life in adults with overweight or obesity: Patient‐reported outcomes from the STEP 1–4 trials
von: Domenica Rubino, et al.
Veröffentlicht: (2024)

Potent incretin‐based therapy for obesity: A systematic review and meta‐analysis of the efficacy of semaglutide and tirzepatide on body weight and waist circumference, and safety
von: Alberte Laura Oest Müllertz, et al.
Veröffentlicht: (2024)

Comment on “Indirect comparative efficacy and safety of tirzepatide 10 and 15 mg versus semaglutide 2.4 mg for the management of obesity and overweight in patients with type 2 diabetes”
von: Manish R. Bhise, et al.
Veröffentlicht: (2025)

Healthcare professionals' perceptions and management of obesity & knowledge of glucagon, GLP‐1, GIP receptor agonists, and dual agonists
von: W. Timothy Garvey, et al.
Veröffentlicht: (2024)

Efficacy and safety of oral semaglutide treatment in a Danish type 2 diabetes outpatient clinic: Real‐world evidence
von: Alexandra A. Weinreich, et al.
Veröffentlicht: (2025)

Real‐world titration, persistence & weight loss of semaglutide and tirzepatide in an academic obesity clinic
von: Jason M. Samuels, et al.
Veröffentlicht: (2025)

Efficacy and safety of once‐weekly subcutaneous semaglutide 2.4 mg for the management of overweight or obesity in Asian populations: A systematic review, meta‐analysis and meta‐regression of randomised trials
von: Hendra Zufry, et al.
Veröffentlicht: (2025)

Body composition changes during weight reduction with tirzepatide in the SURMOUNT ‐1 study of adults with obesity or overweight
von: Michelle Look, et al.
Veröffentlicht: (2025)

Improved health‐related quality of life with tirzepatide versus semaglutide in adults with obesity or overweight from the SURMOUNT ‐5 trial
von: Alpana P. Shukla, et al.
Veröffentlicht: (2025)

Response to “Weight‐loss drugs like Wegovy could lead to an increased risk of fragility fractures in population at risk”
von: Robert F. Kushner, et al.
Veröffentlicht: (2025)

Investigating shared genetic architecture between major depressive disorder and central obesity
von: Ya Zhan, et al.
Veröffentlicht: (2025)

Post‐semaglutide weight regain in females with obesity: Associations with gut microbiota, bile acid metabolism, and central nervous system
von: Ning Wang, et al.
Veröffentlicht: (2026)

Clarification of our response to “The importance of diversity in Obesity articles”
von: Michelle Cardel, et al.
Veröffentlicht: (2024)

Titration and discontinuation of semaglutide for weight management in commercially insured US adults
von: Yunwen Xu, et al.
Veröffentlicht: (2025)

Response to the Letter to the Editor by Athinarayanan
von: Jaime P. Almandoz, et al.
Veröffentlicht: (2024)

Effect of oral semaglutide on energy intake, appetite, control of eating and gastric emptying in adults living with obesity: A randomized controlled trial
von: Maria Buur Nordskov Gabe, et al.
Veröffentlicht: (2024)

Unraveling the obesity paradox in polytrauma patients: survival benefit specifically in individuals with obesity class I
von: Hui‐Tzung Luh, et al.
Veröffentlicht: (2025)

Response to the Letter to the Editor by Bett et al.
von: Jaime P. Almandoz, et al.
Veröffentlicht: (2024)

Effectiveness and safety of once‐weekly subcutaneous semaglutide versus other glucose‐lowering agents in real‐world patients with type 2 diabetes: A retrospective, observational post‐marketing study
von: Chenyang Shi, et al.
Veröffentlicht: (2024)

Tirzepatide 10 and 15 mg versus semaglutide 2.4 mg in people with obesity or overweight with type 2 diabetes: An indirect treatment comparison
von: Emily R. Hankosky, et al.
Veröffentlicht: (2025)

Glycaemic and weight effects of metabolic surgery or semaglutide in diabetes dosage for patients with type 2 diabetes
von: Erik Stenberg, et al.
Veröffentlicht: (2024)

Effectiveness and safety of GLP ‐1 receptor agonists in craniopharyngioma patients with obesity: A multicentre real‐world study
von: Flora Lambert, et al.
Veröffentlicht: (2025)

Comparative safety of glucose‐lowering medications on depression in adults with type 2 diabetes
von: Stephanie A. Hooker, et al.
Veröffentlicht: (2026)

A phase 1, randomized, double‐blind, placebo‐controlled trial investigating the pharmacokinetics, pharmacodynamics, safety and tolerability of oral semaglutide in healthy Chinese subjects
von: Panpan Xie, et al.
Veröffentlicht: (2024)

The effect of semaglutide on intestinal iron absorption in patients with type 2 diabetes mellitus—A pilot study
von: Petra Melis, et al.
Veröffentlicht: (2025)

Effectiveness and safety of daily oral semaglutide in people with type 2 diabetes mellitus switching from sulfonylureas: A real‐world retrospective study
von: Silvana Costa, et al.
Veröffentlicht: (2025)

Sex differences in perceived discrimination among patients with obesity
von: Marianne O. Olaniran, et al.
Veröffentlicht: (2024)

Is the combination of resmetirom and semaglutide useful for the treatment of metabolic dysfunction‐associated steatohepatitis?
von: Stergios A. Polyzos, et al.
Veröffentlicht: (2026)

Modeling potential cost‐effectiveness of tirzepatide versus lifestyle modification for patients with overweight and obesity
von: Meredith M. Hoog, et al.
Veröffentlicht: (2025)

Myocardial mechano‐energetic efficiency is not impaired in patients with metabolically healthy overweight and obesity
von: Chiara Maria Assunta Cefalo, et al.
Veröffentlicht: (2024)

Diabetic kidney disease: The fourth pharmacological pillar may be semaglutide
von: Dario Giugliano, et al.
Veröffentlicht: (2024)

Development and validation of an eating behavior patient‐reported outcome measure in people living with obesity or overweight
von: Donald M. Bushnell, et al.
Veröffentlicht: (2025)

Efficacy and safety of once‐weekly semaglutide 2.4 mg for weight management in participants from China: A prespecified analysis of the STEP 7 randomized clinical trial
von: Weijun Gu, et al.
Veröffentlicht: (2025)

Medical semiology of patients with monogenic obesity: A systematic review
von: Emeline Renard, et al.
Veröffentlicht: (2024)

Effect of semaglutide 2.4 mg on use of antihypertensive and lipid‐lowering treatment in five randomized controlled STEP trials
von: Beverly G. Tchang, et al.
Veröffentlicht: (2025)

Real‐world safety profile of once‐weekly semaglutide in people with type 2 diabetes: Analysis of pooled data from the SemaglUtide Real‐world Evidence (SURE) programme
von: Jean‐François Yale, et al.
Veröffentlicht: (2024)